How can Boston Scientific address the recent 20% decline in physician adoption rates for its RESONATE family of implantable cardioverter defibrillators?

Introduction

Boston Scientific's RESONATE family of implantable cardioverter defibrillators (ICDs) has experienced a concerning 20% decline in physician adoption rates. This analysis will systematically identify, validate, and address the root cause of this issue, considering both immediate and long-term implications for the product and company.

Step 1

Clarifying Questions (3 minutes)

• Considering the specificity of the decline, I'm wondering about the timeframe. Has this 20% decline occurred over the past quarter, or is it a longer-term trend?

Why it matters: Understanding the timeline helps identify potential correlations with product changes or market events. Expected answer: The decline has been observed over the past six months. Impact on approach: A longer timeframe might indicate a systemic issue rather than a short-term fluctuation.

• Given the nature of ICDs, I'm curious about the geographic distribution. Is this decline uniform across all regions, or are there specific areas more affected?

Why it matters: Regional variations could point to localized factors or regulatory changes. Expected answer: The decline is more pronounced in certain regions, particularly in the Northeast and Midwest. Impact on approach: Regional disparities would necessitate a more targeted investigation and potentially tailored solutions.

• Considering the competitive landscape, have there been any significant product launches or updates from competitors during this period?

Why it matters: Competitor actions could be drawing physicians away from the RESONATE family. Expected answer: A major competitor launched a new ICD with enhanced remote monitoring capabilities three months ago. Impact on approach: This would shift focus towards competitive analysis and potential product enhancements.

• Reflecting on potential internal changes, have there been any modifications to the RESONATE product line or associated services in the past year?

Why it matters: Internal changes could have unintended consequences on adoption rates. Expected answer: A software update was rolled out to improve battery life, but some physicians reported issues with the new interface. Impact on approach: This would prioritize investigating the impact of recent product changes and user experience.